Unicycive Therapeutics: Advancing Renal and Cardiovascular Health

Unicycive Therapeutics, represented on the stock exchange under the ticker 'UNCY', is a biopharmaceutical company that focuses on the development of therapies for kidney disease and other severe conditions. The company was co-founded by Dr. Edmund R. LaVoie, an accomplished medicinal chemist, and Sam Salman, an experienced entrepreneur in the biopharmaceutical sector.

Dr. Edmund R. LaVoie, who also serves as Unicycive's Chief Scientific Officer, brings his broad knowledge of medicinal chemistry and drug discovery to the company. Co-founder Sam Salman serves as the Chairman and CEO. Salman, with his extensive experience in clinical development and corporate leadership, helps guide Unicycive's strategic and operational direction.

Complementing the company's leadership is a team of seasoned professionals, including Dr. David M. Charytan, a renowned nephrologist, and Dr. Prabir Ray-Chaudhury, a leading figure in dialysis vascular access. Their expertise greatly contributes to the company's efforts in developing innovative treatments for kidney disease.

Unicycive's product pipeline is focused on addressing significant unmet medical needs in the renal and cardiovascular space. Its lead product candidate, Renazorb, is a highly potent phosphate binder being developed for hyperphosphatemia in patients with chronic kidney disease. Renazorb represents a potentially transformative treatment for this condition, which has limited therapeutic options available.

Also notable is the company's development of SMNH-S-44, a pan SIRT 1-3 activator that has shown potential benefits in preclinical models of kidney disease. This investigational compound represents Unicycive's commitment to creating novel solutions for severe conditions, extending beyond traditional therapeutic approaches.

Unicycive Therapeutics’ story is one of scientific innovation driven by a deep understanding of unmet medical needs. From the vision of its founders to the expertise of its leadership team and its promising drug pipeline, Unicycive is poised to make significant contributions to the treatment of kidney disease and associated conditions.